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ABSTRACT
Background. The majority of South Africans rely on a resource-constrained public healthcare sector, where access to renal
replacement therapy (RRT) is strictly rationed. The incidence of RRT in this sector is only 4.4 per million population (pmp),
whereas it is 139 pmp in the private sector, which serves mainly the 16% of South Africans who have medical insurance.
Data on the outcomes of RRT may influence policies and resource allocation. This study evaluated, for the first time, the
survival of South African patients starting RRT based on data from the South African Renal Registry.
Methods. The cohort included patients with end-stage kidney disease who initiated RRT between January 2013 and
September 2016. Data were collected on potential risk factors for mortality. Failure events included stopping treatment
without recovery of renal function and death. Patients were censored at 1 year or upon recovery of renal function or loss to
follow-up. The 1-year patient survival was estimated using the Kaplan–Meier method and the association of potential risk
factors with survival was assessed using multivariable Cox proportional hazards regression.
Results. The cohort comprised 6187 patients. The median age was 52.5 years, 47.2% had diabetes, 10.2% were human
immunodeficiency virus (HIV) positive and 82.2% had haemodialysis as their first RRT modality. A total of 542 patients died
within 1 year of initiating RRT, and overall 1-year survival was 90.4% [95% confidence interval (CI) 89.6–91.2]. Survival was
similar in patients treated in the private sector as compared with the public healthcare sector [hazard ratio 0.93 (95% CI
0.72–1.21)]. Higher mortality was associated with older age and a primary renal diagnosis of ‘Other’ or ‘Aetiology unknown’.
When compared with those residing in the Western Cape, patients residing in the Northern Cape, Eastern Cape,
Mpumalanga and Free State provinces had higher mortality. There was no difference in mortality based on ethnicity,
diabetes or treatment modality. The 1-year survival was 95.9 and 94.2% in HIV-positive and -negative patients, respectively.
One-fifth of the cohort had no data on HIV status and the survival in this group was considerably lower at 77.1% (P<0.001).
Conclusions. The survival rates of South African patients accessing RRT are comparable to those in better-resourced
countries. It is still unclear what effect, if any, HIV infection has on survival.
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INTRODUCTION
The burden of chronic kidney disease (CKD) in Africa is growing,
reflecting epidemiological transitions on the continent. In their
systematic reviews, Stanifer et al. [1] and Kaze et al. [2] estimated
the population prevalence at 13.9 and 15.8%, respectively, and
report that the brunt of the CKD burden is borne by the sub-
Saharan Africa (SSA) region. Some of the factors driving the
CKD epidemic in Africa include the increasing prevalence of
non-communicable diseases, such as hypertension and diabe-
tes, together with a high burden of infectious diseases (such as
HIV), pregnancy-related diseases, trauma-related complications
and environmental toxins [3].
The incidence of end-stage kidney disease (ESKD) in Africa
is not known, but for those patients who progress to this stage,
access to renal replacement therapy (RRT) with chronic dialy-
sis or kidney transplantation is inequitable [4, 5]. Worldwide, it
is estimated that 80% of dialysis patients reside in Europe,
Japan and the USA [6]. This statistic is even more striking
when considering that it is projected that 70% of patients
reaching ESKD in 2030 will be residents of low-income coun-
tries [6].
As RRT programmes are developed and expanded around
the world, it becomes increasingly important to monitor and re-
port on the success of the treatment. A review by Anand et al. [5]
described 1-year survival on dialysis for the various World
Bank–defined regions using the most populous country from
each region as a proxy. The lowest 1-year survival was found in
Africa (63%), with Nigeria the representative country. This com-
pares poorly with most other regions of the world, where 1-year
survival rates are >85% [5]. Given the resource limitations faced
by the governments of most African countries and the increas-
ing growth of RRT programmes on the continent, it is vital that
quality assurance programmes monitoring survival and other
standards of care are put in place to protect patients and to jus-
tify the use of scarce health resources [7].
Renal registries are critical for quantifying the burden of
ESKD and access to—and outcomes of—RRT, and their absence
in most African countries results in many important knowledge
gaps [8]. South Africa is among the few African countries that
have a national renal registry; this registry covers all provinces
and includes all RRT centres in the country. Since its re-
establishment, annual reports have been published regularly,
beginning with a report of 2012 data [9]. The latest report con-
firms that access to RRT is still very limited, as most South
Africans do not have private medical insurance and must de-
pend on underresourced public sector facilities for their health
care [10, 11]. The overall incidence of RRT in South Africa was 25
per million population (pmp) in 2017, well below the incidence
reported from better-resourced countries such as the USA (370
pmp) and the UK (121 pmp) [12, 13]. The incidence of RRT in the
public sector is only 4.4 pmp, whereas it is 139 pmp in the pri-
vate sector, which serves mainly the 16% of South Africans who
have medical insurance. The prevalence of treated ESKD in the
public sector is 66 pmp, less than one-tenth of the prevalence of
855 pmp in the private sector. In 1994, according to the last re-
port of the previous national registry, most of the RRT was pro-
vided by public sector facilities and the overall prevalence was
70 pmp [9, 14]. There has therefore been no real growth in the
access to RRT for most South Africans over the past 2.5 decades.
Given the steady improvements in data quality and recent
opportunities to link to national records for validation of vital
status, the aim of this study was to evaluate, for the first time,
the survival of incident patients receiving RRT based on data
from the South African Renal Registry (SARR).
MATERIALS ANDMETHODS
Data collection
This cohort study used data collected by the SARR to determine
1-year survival in South African patients receiving RRT. The
details of methods and definitions used by the registry are de-
scribed in the SARR annual reports [11]. In brief, the SARR col-
lects country-wide data on all patients with ESKD who are
treated with RRT. The data collection includes adults and chil-
dren, covers all provinces and covers patients treated in the
public as well as the private healthcare sectors. The list of treat-
ment centres is included in each annual registry report [11].
Centres submit data to the registry upon registration of new
patients and then annually, to provide follow-up information
for December each year. In addition, transfers of treatment mo-
dalities or treatment centres are recorded, and any deaths or
end of treatment events are also recorded. Regarding loss to
follow-up, the SARR assumes that a functioning transplant is
maintained unless there is evidence of a ‘transplant failure’ or
death. A dialysis modality is assumed to continue for 1 year
from the date of the last registry entry and thereafter the pa-
tient is considered lost to follow-up.
The cohort included patients with ESKD who initiated RRT
between 1 January 2013 and 30 September 2016 and survived for
at least 90 days. A cohort of prevalent patients who were alive
on chronic dialysis or had a functioning kidney transplant on 31
December 2015 is described in Supplementary data, Appendix 1.
Data were exported on 5 November 2018 from the SARR
database into Excel files (Microsoft, Redmond, WA, USA) and
imported into Stata version 13 (StataCorp, College Station, TX,
USA) and Enterprise Guide version 5.1 (SAS Institute, Cary, NC,
USA). Prior to analysis, the data were subjected to an extensive
cleaning process that is detailed in Supplementary data,
Appendix 2. Validation of vital status against the database of
the Department of Home Affairs was an important part of this
process. It required the submission of valid South African iden-
tity numbers, which were available for 85% of the patients.
Statistical analysis was conducted with the assistance of the UK
Renal Registry statistics team.
Outcome definitions
The primary outcome was 1-year patient survival after 90 days
of RRT. To study the association of potential risk factors with
patient mortality, demographic and other clinical data were
also used, including ethnicity, the primary renal diagnosis, the
first RRT modality, human immunodeficiency virus (HIV) status,
healthcare sector (public or private) and province of residence.
In South Africa’s healthcare system, the public sector refers to
government-funded medical facilities and services, while the
private sector refers to medical services offered by private prac-
titioners and institutions. Access to the latter depends on an
individual’s ability to pay for these services, usually via private
medical insurance. Failure events were defined as patient death
or discontinuation of RRT without recovery of renal function.
Patients were censored at the date of stopping treatment if they
recovered renal function, emigrated or were lost to follow-up.
Patients on dialysis were categorized as lost to follow-up 1 year
after their last registry entry or other evidence of activity, such
as a laboratory test result. Transplant patients were considered
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lost to follow-up 1 year after a ‘transplant failure’ entry if there
were no subsequent entries recorded [11].
Statistical analysis
One-year patient survival was estimated using the Kaplan–
Meier method. Evidence of a difference in survival was assessed
using the log rank test. The association of potential risk factors
with 1-year patient survival was assessed using multivariable
Cox proportional hazards regression. The statistical significance
of the main effect of each risk factor was assessed by the maxi-
mum likelihood ratio test and Wald statistics. Age group, eth-
nicity, diabetes, primary renal diagnosis, first RRT modality,
healthcare sector (public/private), province of residence and sex
were all modelled individually and adjusted by different suites
of confounders, determined by prior knowledge of whether they
met the criteria for confounding (see Table 2) [15]. To assess
whether the proportional hazard assumption holds, Schoenfeld
residuals from the Cox regression model were examined by the
rank test, Pearson’s correlation coefficients and by modelling
them as time-dependent effects. There was no significant viola-
tion of the proportional hazards assumption in the survival
model.
Missing data were excluded from the statistical analysis.
The percentage of missingness for demographic/clinical factors
is described in Table 1. In the multivariable regression analysis,
92.1–99.8% of complete case data were used depending on
which variables were involved in the models.
Ethical considerations
Approval for the study was granted by the Health Research
Ethics Committee of Stellenbosch University (reference no. N11/
01/028).
RESULTS
The cohort comprised 6187 patients. Baseline variables are sum-
marized in Table 1. The median age at the start of RRT was
52.5 years [interquartile range (IQR) 41.2-62.5 years] and the ma-
jority (56.1%) were in the 40- to 64-year age group. More than
half (53.9%) were Black and most (83.1%) received their treat-
ment in the private sector. Haemodialysis (HD) was the predom-
inant first treatment modality (82.2%).
Nearly half of all patients had diabetes. Hypertensive ne-
phropathy was the most common primary renal diagnosis, fol-
lowed by ESKD of unknown cause and diabetic nephropathy.
A total of 542 patients died within 1 year of initiating RRT.
Overall, 1-year survival was 90.4% [95% confidence interval
(CI) 89.6–91.2] (Supplementary data, Figure S2). Multivariable
analysis of risk factors revealed that lower survival was asso-
ciated with older age, a primary renal diagnosis of ‘Other’ or
‘Unknown’ and residence in specific provinces (Figure 1 and
Table 2). Compared with patients in the 18- to 40-year age
group, older patients were found to have higher adjusted
mortality. Those in the 40- to 64-year age group had a 42%
higher chance of dying [hazard ratio (HR) 1.42 (95% CI 1.05–
1.93)] and the highest mortality was found in patients
>75 years of age [HR 3.40 (95% CI 2.33–4.97)]. Compared with
patients with a primary renal diagnosis of hypertensive renal
disease, the adjusted mortality was higher in patients with
ESKD of unknown aetiology [HR 1.47 (95% CI 1.16–1.86)] and
those categorized as ‘Other’ [HR 1.74 (95% CI 1.16–2.63)].
Patients with diabetes did not have a significant difference in
survival compared with patients without diabetes. Patients
residing in the provinces of the Eastern Cape, Free State,
Mpumalanga and Northern Cape had worse 1-year survival
compared with those residing in the Western Cape. Those re-
siding in the Northern Cape had the highest adjusted mortal-
ity [HR 2.53 (95% CI 1.38–4.63)]. Neither ethnicity, first RRT
modality nor health sector (private/public) were indepen-
dently associated with 1-year survival.
The baseline characteristics of the cohort by HIV status are
summarized in Table 3. Approximately 10% of the patients were
HIV positive. Crude 1-year survival was 95.9% and 94.2% in HIV-
positive and HIV-negative patients, respectively (Figure 2). One-
fifth of the cohort had no data on HIV status and the survival in
this group was considerably lower at 77.1% (P< 0.001). There
were similar proportions of missing data on hepatitis B and C
serological status, with similar survival plots (Supplementary
data, Appendix 3).
DISCUSSION
This study revealed several novel findings. First, South Africans
on RRT have good 1-year survival rates of ~90%, with no differ-
ence between patients treated in the public and private health-
care sectors, even after adjustment for case mix. We found
older age, a primary renal diagnosis of ‘Unknown’ or ‘Other’ and
residence in the provinces of the Northern Cape, Eastern Cape,
Mpumalanga or Free State to be associated with higher mortal-
ity. Furthermore, in those patients with data on HIV status, we
observed similar survival rates between HIV-positive and -nega-
tive patients.
The higher mortality among older patients is a finding con-
sistent with registry data from the USA, Europe, Australia and
New Zealand [16–18]. A multicentre study of 538 incident HD
cases at South Africa’s largest private dialysis provider also
found age to be associated with poorer survival [19]. The
Dialysis Outcomes Practice Patterns Study, which included HD
patients from the USA, Japan and Europe, found diabetes melli-
tus to be associated with higher mortality [20]. Several studies
have described inferior survival in patients with diabetic ne-
phropathy, including a study based on data from the European
Renal Association–European Dialysis and Transplant
Association registry [21]. In our study, diabetes was not inde-
pendently associated with 1-year mortality.
In this study, mortality was higher in incident patients with
ESKD of unknown aetiology. This is a large group, mainly com-
prising patients who present to the health system with ad-
vanced CKD and small kidneys and in whom it is difficult to
make a specific renal diagnosis. The proportion of South
African patients on RRT with an unknown primary renal diag-
nosis (29.4% of the cohort) is much higher than is reported from
countries such as the UK (14.6%) [22] and the USA (3.5%) [16] but
is similar to that seen in African countries such as Sudan
(42.6%), Tunisia (29.2%) and Morocco (37.9%) [23–25]. This group
may have poorer outcomes because it likely includes many late
presenters who have not had the benefit of pre-ESKD specialist
care, a problem more common in resource-constrained settings
such as South Africa.
Although we have previously reported [11] marked differen-
ces in RRT prevalence rates between provinces in South Africa,
in this article we report, for the first time, significant differences
in survival on RRT between provinces. The explanation for
these differences is likely to be complex and include factors
such as the distribution of treatment centres and nephrology
human resources, remoteness or rural dwelling, access to public
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sector RRT programmes and access to kidney transplantation.
The impact of remoteness and rural dwelling is well docu-
mented in developed countries. A study based on US Renal Data
System data found higher mortality to be associated with
remoteness rather than ruralness [26]. A similar study from the
Canadian Organ Replacement Registry reported higher overall
mortality and deaths from infectious causes among HD patients
who lived farther from their attending nephrologist [27].
Table 1. Baseline variables for the study cohort by healthcare sector
Variable All patients (N¼ 6187), n (%) Public sector ( N¼ 1042), n (%) Private sector ( N¼ 5145), n (%)
Age (years), median (IQR) 52.5 (41.2–62.5) 38.0 (28.7–46.3) 55.0 (45.2–64.3)
Age group (years)
<18 82 (1.3) 56 (5.4) 26 (0.5)
18–39 1143 (18.5) 451 (43.3) 692 (13.5)
40–64 3469 (56.1) 501 (48.1) 2968 (57.7)
65–74 1010 (16.3) 26 (2.5) 984 (19.1)
75 483 (7.8) 8 (0.8) 475 (9.2)
Sex
Female 2516 (40.7) 499 (47.9) 2017 (39.2)
Male 3671 (59.3) 543 (52.1) 3128 (60.8)
First RRT modality
HD 5088 (82.2) 430 (41.3) 4658 (90.5)
PD 1049 (17.0) 591 (56.7) 458 (8.9)
Transplant 50 (0.8) 21 (2.0) 29 (0.6)
Ethnicity
Black 3338 (53.9) 689 (66.1) 2649 (51.5)
White 1086 (17.6) 52 (5.0) 1034 (20.1)
Mixed ancestry 865 (14.0) 224 (21.5) 641 (12.5)
Indian/Asian 805 (13.0) 57 (5.5) 748 (14.5)
Other/Unknown 93 (1.5) 20 (1.9) 73 (1.4)
Diabetes
Diabetes present 2879 (46.5) 199 (19.1) 2680 (52.1)
No diabetes 2923 (47.2) 796 (76.4) 2127 (41.3)
No data 385 (6.2) 47 (4.5) 338 (6.6)
Primary diagnosis
Hypertensive renal disease 2246 (36.3) 212 (20.4) 2034 (39.5)
Aetiology unknown 1824 (29.4) 544 (52.2) 1280 (24.9)
Diabetic nephropathy 1252 (20.2) 41 (3.9) 1211 (23.5)
Glomerular diseasea 479a (7.7) 176 (16.9) 303 (5.9)
Cystic kidney disease 124 (2.0) 17 (1.6) 107 (2.1)
Otherb 262 (4.2) 52 (5.0) 210 (4.1)
Province
Eastern Cape 647 (10.5) 119 (11.4) 528 (10.3)
Free State 361 (5.8) 102 (9.8) 259 (5.0)
Gauteng 1596 (25.8) 134 (12.9) 1462 (28.4)
KwaZulu-Natal 1532 (24.8) 250 (24.0) 1282 (24.9)
Limpopo 293 (4.7) 62 (6.0) 231 (4.5)
Mpumalanga 214 (3.5) 3 (0.3) 211 (4.1)
North West 307 (5.0) 59 (5.7) 248 (4.8)
Northern Cape 102 (1.7) 31 (3.0) 71 (1.4)
Western Cape 1135 (18.3) 282 (27.1) 853 (16.6)
Hepatitis B status
Carrier 102 (1.7) 13 (1.3) 89 (1.7)
Immune 440 (7.1) 229 (22.0) 211 (4.1)
Negative 4586 (74.1) 595 (57.1) 3991 (77.6)
No data 1059 (17.1) 205 (19.7) 854 (16.6)
Hepatitis C status
Positive 31 (0.5) 5 (0.5) 26 (0.5)
Negative 4817 (77.9) 739 (70.9) 4078 (79.3)
No data 1339 (21.6) 298 (28.6) 1041 (20.2)
HIV status
Positive 633 (10.2) 104 (10.0) 529 (10.3)
Negative 4324 (69.9) 681 (65.4) 3643 (70.8)
No data 1230 (19.9) 257 (24.7) 973 (18.9)
aIncludes 94 patients with nephropathy related to HIV.
bIncludes all other primary renal diagnoses, comprising 4.2% of the cohort.
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Developing countries such as South Africa are likely to have a
greater proportion of remote or rural patients requiring RRT
[28]. A recent study comparing rural and urban South African
CKD patients attending a tertiary hospital in the province of
KwaZulu-Natal found that rural patients presented with more
advanced renal disease and had higher rates of HIV infection
[28]. Another South African study, at a private–public dialysis
centre in Limpopo, found rural dwelling to be associated with
higher all-cause mortality in patients treated with continuous
ambulatory peritoneal dialysis [29].
We studied incident patients who were alive for at least
90 days following the initiation of RRT. High mortality in the
first 90 days following the start of RRT has been highlighted in
studies conducted in other African countries [30–32]. The sur-
vival rates reported here are in line with the findings of two
other South African studies that included the first 90 days fol-
lowing the initiation of treatment [19, 33].
The survival rates of South Africans on RRT are comparable
to those of better-resourced countries such as the UK (90.4%)
and USA (81.1%) and higher than those of the few African coun-
tries with survival data, including Cameroon (73.2%) and
Ethiopia (42.1%) [13, 16, 30, 34]. Our cohort differed from those of
the USA and UK with regards to age, in that our patients were
younger, with a lower proportion of patients 65 years of age.
This may be at least partly explained by the strict rationing of
RRT in the South African public healthcare sector.
Table 2. HRs for risk factors of interest by univariable and multivariable Cox regression
Variable
Univariable model Multivariable model
HR (95% CI) P-value
Adjusted for
confoundera HR (95% CI) P-value
Age group (years)
<18 1.61 (0.78–3.35) <0.01 Healthcare sector,
ethnicity
1.57 (0.75–3.28) <0.01
18–40 1 1
40–64 1.33 (1.03–1.73) 1.33 (1.01–1.74)
65–74 1.65 (1.22–2.24) 1.68 (1.22–2.32)
75 3.02 (2.2–4.14) 3.10 (2.21–4.35)
Ethnicity
White 1 0.08 Age, healthcare
sector
1 0.40
Black 0.83 (0.66–1.03) 1.00 (0.80–1.26)
Mixed ancestry 0.68 (0.5–0.92) 0.79 (0.58–1.09)
Indian/Asian 0.91 (0.68–1.22) 0.97 (0.73–1.3)
Diabetes
Non-diabetic 1 0.01 Age, ethnicity and
healthcare sector
1 0.21
Diabetic 1.28 (1.07–1.53) 1.13 (0.93–1.38)
Primary diagnosis
Cystic kidney disease 0.40 (0.15–1.09) <0.01 Age, ethnicity and
healthcare sector
0.43 (0.16–1.15) <0.01
Glomerular disease 0.91 (0.63–1.32) 1.08 (0.74–1.58)
Hypertensive renal disease 1 1
Diabetic nephropathy 1.10 (0.86–1.4) 1.03 (0.81–1.32)
Aetiology unknown 1.40 (1.14–1.71) 1.47 (1.19–1.82)
Other 1.79 (1.24–2.59) 1.80 (1.24–2.62)
First modality
TX 0.82 (0.26–2.56) 0.11 Age, ethnicity, diabe-
tes, primary diag-
nosis and
healthcare sector
0.63 (0.15–2.6) 0.24
PD 0.77 (0.60–0.98) 0.78 (0.57–1.06)
HD 1 1
Healthcare sector
Private 1.19 (0.94–1.50) 0.16 Age, ethnicity 0.93 (0.72–1.21) 0.61
Public 1 1
Province
North West 0.78 (0.46–1.35) <0.01 Ethnicity and
healthcare sector
0.78 (0.45–1.38) <0.01
Western Cape 1 1
Limpopo 1.20 (0.75–1.92) 1.22 (0.74–2.01)
KwaZulu-Natal 1.37 (1.03–1.82) 1.33 (0.94–1.86)
Gauteng 1.46 (1.11–1.93) 1.38 (1.01–1.90)
Eastern Cape 1.52 (1.09–2.13) 1.54 (1.07–2.22)
Free State 1.84 (1.26–2.68) 1.83 (1.21–2.76)
Mpumalanga 1.83 (1.16–2.88) 1.75 (1.08–2.85)
Northern Cape 2.51 (1.46–4.31) 2.45 (1.38–4.35)
Sex
Male 1 0.84 Age 1 0.99
Female 0.98 (0.83–1.17) 1.00 (0.84–1.19)
aThe confounders are selected based on the prior knowledge that they have an association with mortality and are associated with the variable of interest but not an ef-
fect of the variable of interest nor a factor in the causal pathway of mortality.
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In the light of South Africa’s HIV epidemic, it is important to
consider the survival of HIV-positive patients on RRT who, prior
to 2007, were largely excluded from public sector RRT pro-
grammes [35, 36]. A recent study at a large public sector hospital
in the province of KwaZulu-Natal reported 1-year survival of
81.5% for HIV-positive patients receiving RRT and suggested
that even those patients with low CD4 cell counts or who are
not yet established on antiretroviral therapy should be able to
access RRT [37]. We found that patients with missing data for
HIV have worse survival compared with patients with HIV data,
and even worse than that of patients who tested positive for
HIV. We observed a very similar picture when analysing the im-
pact of hepatitis B and C status; survival was lower among
patients in whom both hepatitis B and C status were unknown
(Supplementary data, Appendix 3). The submission of data on
viral serology to the SARR is currently optional and we speculate
that patients who survive longer are more likely to have these
optional elements entered on one of the annual rounds of data
submission. It is also possible that there may be underreporting
of HIV in the group with missing HIV data. Nearly one-quarter
of our patients had missing data on HIV, hepatitis B and hepati-
tis C status and this limits our ability to draw any firm conclu-
sions about their impact on survival.
Strengths and limitations
This is the first report of survival on RRT at a national level in
an SSA country using data collected as part of a national renal
registry. With the SARR now providing the platform for five sub-
Saharan countries as part of the African Renal Registry, this
FIGURE 1: HRs by multivariable Cox regression for each of the potential risk factors for 1-year survival in incident patients on RRT. Age group, ethnicity, diabetes, pri-
mary renal diagnosis, first treatment modality, healthcare sector (public/private), province of residence and sex are all modelled individually and adjusted by a differ-
ent suite of confounders. The confounders are selected based on the prior knowledge that they have an association with mortality and are associated with the variable
of interest but not an effect of the variable of interest nor a factor in the causal pathway of mortality. Age group was adjusted for healthcare sector and ethnicity; eth-
nicity was adjusted for age and healthcare sector; diabetes was adjusted for age, ethnicity and healthcare sector; primary renal diagnosis was adjusted for age, ethnic-
ity and healthcare sector; first modality was adjusted for age, ethnicity, diabetes, primary diagnosis and healthcare sector; healthcare sector was adjusted for age and
ethnicity; province was adjusted for ethnicity and healthcare sector and sex was adjusted for age.
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represents a significant evolution of quality assurance in RRT in
Africa [8]. The use of linkage to a national death register to vali-
date mortality status is state of the art and addresses many his-
torical concerns about outcomes on RRT in Africa. Our study
had several limitations, however. South African identity
numbers were not available for ~15% of our patients and we
could not cross-check their vital status with the database of the
Department of Home Affairs. For these patients, we relied on
data from the treatment centres and dialysis provider compa-
nies. The observational nature of the study meant that we could
Table 3. Baseline characteristics by HIV status
Variable HIV negative (N¼ 4324), n (%) HIV positive (N¼ 633), n (%) HIV unknown (N¼ 1230), n (%)
Age (years), median (IQR) 54.0 (42.1–63.9) 45.3 (38.1–52.6) 52.4 (40.3–61.9)
Age group (years)
<18 63 (1.5) 5 (0.8) 14 (1.1)
18–39 751 (17.4) 144 (22.8) 248 (20.2)
40–64 2337 (54.1) 455 (71.9) 677 (55.0)
65–74 799 (18.5) 24 (3.8) 187 (15.2)
75 374 (8.7) 5 (0.8) 104 (8.5)
Sex
Female 1766 (40.8) 258 (40.8) 492 (40.0)
Male 2558 (59.2) 375 (59.2) 738 (60.0)
First RRT modality
HD 3543 (81.9) 548 (86.6) 997 (81.1)
PD 746 (17.3) 82 (13.0) 221 (18.0)
Transplant 35 (0.8) 3 (0.5) 12 (1.0)
Ethnicity
Black 1985 (45.9) 598 (94.5) 755 (61.4)
White 890 (20.6) 6 (1.0) 190 (15.5)
Mixed ancestry 762 (17.6) 15 (2.4) 88 (7.2)
Indian/Asian 617 (14.3) 9 (1.4) 179 (14.6)
Other/Unknown 70 (1.6) 5 (0.8) 18 (1.5)
Diabetes
Diabetes present 2124 (49.1) 218 (34.4) 537 (43.7)
No diabetes 2056 (47.6) 386 (61.0) 481 (39.1)
No data 144 (3.3) 29 (4.6) 212 (17.2)
Primary diagnosis
Hypertensive renal disease 1659 (38.4) 232 (36.7) 355 (28.9)
Aetiology uncertain 1048 (24.2) 195 (30.8) 581 (47.2)
Diabetic nephropathy 999 (23.1) 80 (12.6) 173 (14.1)
Glomerular diseasea 317 (7.3) 110 (17.4) 52 (4.2)
Cystic kidney disease 110 (2.5) 4 (0.6) 10 (0.8)
Otherb 191 (4.4) 12 (1.9) 59 (4.8)
Healthcare sector
Public 681 (15.8) 104 (16.4) 257 (20.9)
Private 3643 (84.3) 529 (83.6) 973 (79.1)
Province
Eastern Cape 449 (10.4) 76 (12.0) 122 (9.9)
Free State 255 (5.9) 55 (8.7) 51 (4.2)
Gauteng 1065 (24.6) 153 (24.2) 378 (30.7)
KwaZulu-Natal 962 (22.3) 202 (31.9) 368 (29.9)
Limpopo 201 (4.7) 33 (5.2) 59 (4.8)
Mpumalanga 125 (2.9) 42 (6.6) 47 (3.8)
North West 156 (3.6) 28 (4.4) 123 (10.0)
Northern Cape 76 (1.8) 3 (0.5) 23 (1.9)
Western Cape 1035 (23.9) 41 (6.5) 59 (4.8)
Hepatitis B status
Carrier 65 (1.5) 30 (4.7) 7 (0.6)
Immune 374 (8.7) 33 (5.2) 33 (2.7)
Negative 3797 (87.8) 525 (82.9) 264 (21.5)
No data 88 (2.0) 45 (7.1) 926 (75.3)
Hepatitis C status
Positive 27 (0.6) 2 (0.3) 2 (0.2)
Negative 4024 (93.1) 547 (86.4) 246 (20.0)
No data 273 (6.3) 84 (13.3) 982 (79.8)
aIncludes nephropathy related to HIV.
bIncludes all other primary renal diagnoses.
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only determine associations and not causality. Furthermore, de-
spite concerted efforts to clean the data (as detailed in
Supplementary data, Appendix 2), there were residual missing
data, particularly with regards to HIV, hepatitis B and hapatitis
C serological status. We excluded patients who died within the
first 90 days of initiating RRT and will need to analyse these
early deaths in a subsequent study.
CONCLUSIONS
The 1-year survival of South African patients on RRT is favour-
able and compares well with survival rates reported from
better-resourced countries. There are marked differences in sur-
vival rates between provinces, however, and these will need to
be presented to health policymakers in South Africa and inves-
tigated in the future through quality assurance and research. It
is still unclear what impact, if any, HIV status has on patient
survival. There is no difference in 1-year survival between the
public and private healthcare sectors. The findings of this study
should encourage policymakers to increase access to life-
sustaining RRT in the public sector.
SUPPLEMENTARY DATA
Supplementary data are available at ckj online.
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